Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 13/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2388142 | 1.00 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL2389101 | 1.00 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL4987772 | 0.93 | CA2 (0.46) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL4987756 | 0.93 | CA2 (0.46) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL24687980 | 0.89 | TDP1 (0.50) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL361540 | 0.89 | TDP1 (0.50) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL31059571 | 0.89 | TDP1 (0.50) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL12493912 | 0.87 | TDP1 (0.53) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL12493914 | 0.87 | TDP1 (0.53) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL8314800 | 0.86 | TDP1 (0.56) | CA1CA2CA7CYP2D6CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118851940-B | Preparation method of (S) -3-amino butyronitrile hydrochloride | 山东佰隆医药有限公司 | 2024-12-27 | — | — | CN | claimed |
| CN-118851940-A | Preparation method of (S) -3-amino butyronitrile hydrochloride | 山东佰隆医药有限公司 | 2024-10-29 | — | — | CN | claimed |
| CN-119684313-A | Macrocyclic compound and preparation method and application thereof | 上海爱科百发生物医药技术股份有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-118851940-B | Preparation method of (S) -3-amino butyronitrile hydrochloride | 山东佰隆医药有限公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-118851940-A | Preparation method of (S) -3-amino butyronitrile hydrochloride | 山东佰隆医药有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-118851940-A | Preparation method of (S) -3-amino butyronitrile hydrochloride | 山东佰隆医药有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-118638017-A | Preparation method and application of chiral 4-aminopentanol | 上海华默西医药科技有限公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-116406272-A | DNA-PK selective inhibitor and preparation method and application thereof | 首药控股(北京)股份有限公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-110526930-B | anti-HIV (human immunodeficiency virus) sulfur-containing polycyclic-hydroxypyridone formamide analogue and application thereof | 莫云芬 | 2022-06-03 | — | — | CN | disclosed |
| WO-2022017368-A1 | DNA-PK SELECTIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 首药控股(北京)股份有限公司 | 2022-01-27 | — | — | WO | disclosed |
| WO-2019051265-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AND USES THEREOF | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2019-03-14 | — | — | WO | disclosed |
| EP-1970360-A1 | Method for producing alcohols | Takasago International Corporation (JP) | 2008-09-17 | — | — | EP | disclosed |
| US-20080114010-A1 | Novel Substituted Imidazole Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-05-15 | — | — | US | disclosed |
| US-7301021-B2 | Substituted imidazole compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| CN-1134420-C | Novel substituted imidazole compounds | �������۸��¼��������������ι�˾ | 2004-01-14 | — | — | CN | disclosed |
| US-20030114452-A1 | Novel substituted imidazole compounds | SMITHKLINE BEECHAM CORPORATION | 2003-06-19 | — | — | US | disclosed |
| US-6489325-B1 | INHIBITORS OF CSBP/P38, ONE OF SEVERAL KINASES INVOLVED IN A STRESS-RESPONSE SIGNAL TRANSDUCTION, DECREASE THE SYNTHESIS OF A WIDE VARIETY OF PRO-INFLAMMATORY PROTEINS INCLUDING, IL-6, IL-8, GM-CSF, AND COX-2 | SMITHKLINE BEECHAM CORPORATION | 2002-12-03 | — | — | US | disclosed |
| CN-1261277-A | Novel substituted imidazole compounds | SMITHKLINE BEECHAM CORP (US) | 2000-07-26 | — | — | CN | disclosed |
| EP-0644873-B1 | ORNITHINE DECARBOXYLASE INHIBITING BRANCHED AMINOOXY AMINO ALKANE DERIVATIVES | CIBA GEIGY AG (CH) | 1997-03-12 | — | — | EP | disclosed |
| US-5610195-A | ANTITUMOR AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114452-A1 | Novel substituted imidazole compounds | CREBBP, MAPKAPK2, ATF1 | CA1 4578/4885CA2 3710/4885CA7 4331/4885 |
| US-20080114010-A1 | Novel Substituted Imidazole Compounds | CREBBP, MAPKAPK2, ATF1 | CA1 4578/4885CA2 3710/4885CA7 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.